Theriva Biologics, Inc.

TOVX

Theriva Biologics, Inc.

TOVX

Insider Sentiment (TTM):

Last Purchase:2023-06-07Last Sale:-Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:1,712,311Shares Outstanding:41,072,725Institutional Ownership Pct.:4.17%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	11	14	13	8	12	10	12	16	17	18	23	31
Grants Receivable Current	2	2	3	2	2	2	3	2	2	2	2	1
Prepaid Expense And Other Assets Current	1	1	1	1	1	1	1	1	1	2	2	2
Assets Current	14	17	17	10	15	12	16	20	20	22	27	35
Assets Noncurrent
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Restricted Cash Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	2	2	1	1	1	1	1	1	2	2	2	2
Intangible Assets Net Excluding Goodwill	19	19	20	20	20	18	17	19	19	19	20	19
Assets	35	38	38	31	36	32	35	40	42	49	55	62
Liabilities And Stockhold…
Liabilities Current
Goodwill	-	-	-	-	-	-	0	-	1	6	6	5
Accounts Payable Current	1	1	1	1	1	0	1	1	1	1	1	1
Accrued Liabilities Current	6	6	6	8	9	4	3	4	3	3	3	6
Business Combination Contingent Consideration Liab…	3	1	-	-	-	1	-	-	-	-	-	-
Employee Related Liabilities Current	0	0	0	1	1	1	1	1	1	1	2	1
Loans Payable Current	0	0	0	0	0	0	0	0	0	0	0	0
Contract With Customer Liability Current	-	-	-	-	-	-	-	-	-	-	1	1
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	0	0	0
Liabilities Current	12	10	10	11	12	8	8	7	7	6	7	9
Liabilities Noncurrent
Business Combination Contingent Consideration Liab…	7	9	10	11	10	6	7	7	6	6	6	6
Long Term Loans Payable	2	2	2	2	2	2	0	0	0	0	0	0
Deferred Income Tax Liabilities Net	-	-	-	-	-	-	-	-	-	-	-	0
Operating Lease Liability Noncurrent	1	2	0	0	1	1	1	1	1	1	1	2
Contract With Customer Liability Noncurrent	-	-	-	-	-	-	-	-	-	-	1	1
Liabilities	23	23	23	24	25	17	16	15	15	15	16	18
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	376	376	374	363	362	356	356	355	350	347	347	346
Treasury Stock Value	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Accumulated Other Comprehensive Income Loss Net Of…	0	0	1	1	1	-1	-1	0	-1	-1	0	-1
Temporary Equity
Retained Earnings Accumulated Deficit	-364	-361	-359	-357	-352	-339	-335	-331	-323	-314	-309	-304
Stockholders Equity	12	15	15	7	11	15	19	25	26	31	37	41
Liabilities And Stockholders Equity	35	38	38	31	36	32	35	40	42	49	55	62
Preferred Stock Shares Authorized	-	-	-	10	10	10	-	-	-	-	-	-
Preferred Stock Shares Issued	-	-	-	0	0	0	-	-	-	-	-	-
Preferred Stock Shares Outstanding	-	-	-	0	0	0	-	-	-	-	-	-
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	350	350	350	350	350	350	350	350	350	350	350	350
Common Stock Shares Issued	46	46	36	10	9	3	3	3	1	1	1	1
Shares Outstanding	46	46	36	10	9	3	3	25	1	1	1	1
Treasury Stock Common Shares	0	0	0	0	0	0	0	0	1	1	0	1
Series C Convertible Preferred Stock	-	-	-	-	-	-	0	-0	0	0	0	0
Series D Convertible Preferred Stock	-	-	-	-	-	-	0	-0	0	0	0	0
Temporary Equity Shares Authorized	-	-	-	-	-	-	10	10	10	10	10	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-26.32%	-34.21%	-42.11%	-	-	-	-	-	-	-	-	-
2025	-17.54%	-22.81%	-24.56%	-4.76%	0.00%	-26.19%	-23.33%	-13.33%	-40.00%	27.78%	116.67%	55.56%
2024	-40.48%	-42.86%	-33.33%	-16.76%	-68.00%	-62.10%	-11.19%	11.19%	-11.19%	-19.15%	0.71%	-67.38%
2023	-	-	-	-	-	-	25.00%	2.27%	15.91%	-14.29%	-24.49%	-46.94%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	1.13	1.63	1.74	0.90	1.19	1.53	2.15	2.67	2.88	3.60	4.07	3.98
Quick Ratio	1.07	1.57	1.64	0.84	1.12	1.42	1.96	2.49	2.68	3.33	3.71	3.72
Working Capital	1.56M	6.49M	7.45M	-1.10M	2.35M	4.33M	8.70M	12.21M	12.87M	15.65M	20.67M	26.02M
Leverage & Debt
Debt to Equity	1.86	1.48	1.49	3.58	2.37	1.08	0.85	0.63	0.57	0.47	0.42	0.43
Debt Ratio	0.65	0.60	0.60	0.78	0.70	0.52	0.46	0.39	0.35	0.30	0.28	0.29
Efficiency & Turnover
Asset Turnover TTM	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.29	-0.56	-2.08	-2.71	-4.38	-8.92	-19.03	-23.53	-28.71	-27.75	-28.48	-28.33
Free Cash Flow Per Share TTM	-0.28	-0.35	-1.38	-1.91	-2.68	-6.04	-12.56	-16.61	-23.22	-26.93	-29.81	-26.50
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-3,974.67%	-7,253.67%	-	-	-	-	-	-	-	-	-	-
Net Profit Margin TTM	-4,376.00%	-7,656.33%	-	-	-	-	-	-	-	-	-	-
Growth Metrics
Net Income Growth (1Y)	-55.58%	-7.43%	-1.57%	-1.88%	32.72%	30.34%	39.81%	38.22%	8.64%	-4.29%	-6.79%	4.36%
EPS Growth (1Y)	-93.46%	-93.73%	-89.07%	-88.50%	-84.75%	-67.87%	-33.19%	-16.93%	-15.04%	-15.59%	-11.30%	-2.98%
Valuation Metrics
P/E TTM	-0.87	-0.36	-0.10	-0.15	-0.10	-0.12	-0.09	-0.06	-0.21	-0.42	-0.38	-0.48
P/B TTM	0.94	0.53	0.17	0.59	0.27	0.20	0.12	0.06	0.18	0.26	0.19	0.22
P/S TTM	38.24	27.38	-	-	-	-	-	-	-	-	-	-
Market Cap	11.47M	8.21M	2.55M	3.97M	2.90M	3.06M	2.36M	1.57M	4.65M	8.06M	6.93M	9.20M
Enterprise Value	126.17K	-6.23M	-10.50M	-3.55M	-9.21M	-7.00M	-9.28M	-14.88M	-11.98M	-10.24M	-16.29M	-21.99M
Calculated Values
Free Cash Flow TTM	-12.76M	-14.40M	-16.70M	-18.51M	-18.09M	-16.81M	-16.94M	-18.84M	-18.01M	-18.47M	-19.21M	-18.07M
Net Debt	-11.35M	-14.44M	-13.05M	-7.52M	-12.11M	-10.06M	-11.64M	-16.45M	-16.63M	-18.30M	-23.22M	-31.19M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2023-06-07Purchase

Owner: Shallcross, Steven A

Title: CEO and CFO

Shares: 14,000

Price/Share: $0.69

Value: $9,660.00

Shares Owned: 250,000

Relationship: Director,Officer

Ownership: Direct

2023-06-06Purchase

Owner: Shallcross, Steven A

Title: CEO and CFO

Shares: 26,000

Price/Share: $0.63

Value: $16,380.00

Shares Owned: 236,000

Relationship: Director,Officer

Ownership: Direct

2023-02-10Purchase

Owner: Shallcross, Steven A

Title: CEO and CFO

Shares: 25,000

Price/Share: $1.04

Value: $26,000.00

Shares Owned: 210,000

Relationship: Director,Officer

Ownership: Direct

2023-02-02Purchase

Owner: Shallcross, Steven A

Title: CEO and CFO

Shares: 25,000

Price/Share: $0.94

Value: $23,500.00

Shares Owned: 185,000

Relationship: Director,Officer

Ownership: Direct

2023-01-25Purchase

Owner: Shallcross, Steven A

Title: CEO and CFO

Shares: 25,000

Price/Share: $0.87

Value: $21,750.00

Shares Owned: 160,000

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2023-06-07	Shallcross, Steven A	Director,Officer	CEO and CFO	Direct	Purchase	14,000	0.69	$9,660.00	250,000	4
2023-06-06	Shallcross, Steven A	Director,Officer	CEO and CFO	Direct	Purchase	26,000	0.63	$16,380.00	236,000	4
2023-02-10	Shallcross, Steven A	Director,Officer	CEO and CFO	Direct	Purchase	25,000	1.04	$26,000.00	210,000	4
2023-02-02	Shallcross, Steven A	Director,Officer	CEO and CFO	Direct	Purchase	25,000	0.94	$23,500.00	185,000	4
2023-01-25	Shallcross, Steven A	Director,Officer	CEO and CFO	Direct	Purchase	25,000	0.87	$21,750.00	160,000	4
2023-01-20	Shallcross, Steven A	Director,Officer	CEO and CFO	Direct	Purchase	25,000	0.75	$18,750.00	135,000	4
2022-12-29	Shallcross, Steven A	Director,Officer	CEO and CFO	Direct	Purchase	100,000	0.44	$44,000.00	110,000	4
2021-05-10	Shallcross, Steven A	Director,Officer	CEO and CFO	Direct	Purchase	50,000	0.49	$24,500.00	100,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

4.17%

Inst. Shares: 1,712,311

Shares Outstanding: 41,072,725

2025-12-31

10.67%

Inst. Shares: 1,295,507

Shares Outstanding: 12,140,697

2025-09-30

4.03%

Inst. Shares: 390,165

Shares Outstanding: 9,676,521

2025-06-30

3.81%

Inst. Shares: 256,954

Shares Outstanding: 6,752,953

2025-03-31

6.85%

Inst. Shares: 190,680

Shares Outstanding: 2,782,449

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	1,712,311	41,072,725	4.17%
2025-12-31	1,295,507	12,140,697	10.67%
2025-09-30	390,165	9,676,521	4.03%
2025-06-30	256,954	6,752,953	3.81%
2025-03-31	190,680	2,782,449	6.85%
2024-12-31	34,470	1,348,126	2.56%
2024-09-30	479,620	1,134,391	42.28%
2024-06-30	1,396,578	775,736	180.03%
2024-03-31	723,016	685,923	105.41%
2023-12-31	953,933	644,282	148.06%
2023-09-30	1,008,294	681,708	147.91%
2023-06-30	955,921	15,166,209	6.30%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Theriva Biologics, Inc. (TOVX) — SEC Financial Statements & Analysis

Theriva Biologics, Inc. (TOVX) is a pharmaceutical preparations company, incorporated in NV. Theriva Biologics, Inc. trades on NYSE as: TOVX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Theriva Biologics, Inc. reported a Debt-to-Equity ratio of 1.86x, a Price-to-Sales (P/S) ratio of 38.24x (TTM), a Price-to-Book (P/B) ratio of 0.94x (TTM), at a market cap of $11.47M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 1.86x
P/S TTM: 38.24x
P/B TTM: 0.94x
Market Cap: $11.47M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Theriva Biologics, Inc. in?

Theriva Biologics, Inc. (TOVX) operates in the Pharmaceutical Preparations industry.

What is TOVX's market cap?

Theriva Biologics, Inc. (TOVX) has a market capitalization of $11.47M as of 2026-06-30.

What exchange does TOVX trade on?

Theriva Biologics, Inc. (TOVX) trades on the NYSE.

Where is Theriva Biologics, Inc. incorporated?

Theriva Biologics, Inc. is incorporated in NV.